Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy  by Baudoux, Thomas E.R. et al.
Probenecid prevents acute tubular necrosis in
a mouse model of aristolochic acid nephropathy
Thomas E.R. Baudoux1,6,7, Agnieszka A. Pozdzik1,2,7, Volker M. Arlt3, Eric G. De Prez1, Marie-He´le`ne
Antoine1, Nathalie Quellard4,5, Jean-Michel Goujon4,5 and Joe¨lle L. Nortier1,2
1Experimental Nephrology Unit, Faculty of Medicine, Universite´ Libre de Bruxelles, Brussels, Belgium; 2Nephrology Department, Erasme
Hospital, Universite´ Libre de Bruxelles, Brussels, Belgium; 3Analytical and Environmental Sciences Division, MRC-HPA Centre for
Environment and Health, King’s College London, London, UK; 4Department of Pathology and Electron Microscopy, CHU La Miletrie,
Poitiers, France and 5INSERM U 1082, Poitiers, France
Experimental aristolochic acid nephropathy is characterized
by early tubulointerstitial injury followed by fibrosis,
reproducing chronic lesions seen in humans. In vitro,
probenecid inhibits aristolochic acid entry through organic
anion transporters, reduces specific aristolochic acid-DNA
adduct formation, and preserves cellular viability. To test this
in vivo, we used a mouse model of aristolochic acid
nephropathy displaying severe tubulointerstitial injuries
consisting of proximal tubular epithelial cell necrosis
associated to transient acute kidney injury followed by
mononuclear cell infiltration, tubular atrophy, and interstitial
fibrosis. Treatment with probenecid prevented increased
plasma creatinine and tubulointerstitial injuries, and reduced
both the extent and the severity of ultrastructural lesions
induced by aristolochic acid, such as the loss of brush border,
mitochondrial edema, and the disappearance of
mitochondrial crests. Further, the number of proliferating cell
nuclear antigen–positive cells and total aristolochic acid-DNA
adducts were significantly reduced in mice receiving
aristolochic acid plus probenecid compared with mice
treated with aristolochic acid alone. Thus, we establish the
nephroprotective effect of probenecid, an inhibitor of
organic acid transporters, in vivo toward acute proximal
tubular epithelial cell toxicity in a mouse model of
aristolochic acid nephropathy.
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Human aristolochic acid nephropathy (AAN) is a tubuloin-
terstitial (TI) nephritis reported after intake of herbal
remedies containing aristolochic acid (AA).1,2 It is histolo-
gically characterized by a typical corticomedullary gradient of
interstitial fibrosis and the progressive atrophy of proximal
tubules, resulting in the rapid deterioration of renal function
to the end stage.3,4 AA intoxication also leads to the
formation of specific AA-DNA adducts, which are premuta-
genic lesions involved in the development of AAN-associated
urothelial cancer, and their long-term presence in renal tissue
is used as a biomarker of AA exposure.5,6
AA-induced TI nephritis was experimentally reproduced in
rabbits, mice, and rats.7–10 A biphasic evolution of TI lesions
was identified in our Wistar rat model.11,12 In the early, so-
called acute phase, transient tubular necrosis located in the S3
segment (proximal tubular epithelial cells (PTECs)) and
mononuclear cell infiltration are observed; later, in the so-
called chronic phase, tubular atrophy and interstitial fibrosis are
clearly the prominent features. In this step-by-step model,
inflammatory cells were proposed as the physiopathological
link between both phases.11 In vitro data early confirmed that
PTECs were the target of AA,13 suggesting the presence of
specific molecular mechanisms responsible for the accumula-
tion of AA in PTECs. The excretion of numerous organic
anions (OAs), including endogenous metabolites, through
PTECs is actually achieved via unidirectional transcellular
transport, involving the uptake of OAs from the blood across
the basolateral membrane and their extrusion across the apical
membrane into the tubular lumen. OA transporters (OATs)
have a key role in this process. At least 11 isoforms of OATs
have been identified; a majority of them was found in the
kidney. OATs are exchangers linked to two other transporters,
the sodium dicarboxylate cotransporter and the sodium-
potassium ATPase. OAs are taken up by OAT 1 and/or 3 in the
basolateral membrane of the proximal tubule. This uptake is
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processed in parallel to the countertransport of a-ketogluta-
rate. The drug then crosses the cell and is excreted in the lumen
of the tubule.14,15 The activity of OATs has been associated with
proximal tubular injury due to the accumulation of toxics,
such as uremic toxins, drugs, and mercuric species.14–17 In
human embryonic kidney cells (HEK293) and Xenopus laevis
oocytes, three human isoforms (OAT1, OAT3, or OAT4) were
reported to have a role in intracellular accumulation of AA.18,19
Moreover, probenecid (PBN) blocked AA entry by inhibition
of human OATs, reducing the formation of AA-DNA adduct,19
and preserved cell viability.18
We investigated this last aspect in vivo in a mouse model of
AAN. We hypothesized that PBN, by reducing AA entry
through OATs, could protect PTECs against lesions, preventing
AA-DNA adduct formation, and thus preserve cell viability.
RESULTS
Ninety-six mice C57BL/6 were randomly assigned to four
groups of 24 animals each. According to group, mice were
injected with AA, AAþ PBN, or solvent (polyethylene glycol
(PEG))þ PBN. The control group was injected with PEG
(Figure 1). AA (5mg/kg body weight) or PEG was injected once
a day and PBN (150mg/kg body weight) twice a day. These
dosing regimens of PBN have been shown to inhibit OAT.20
Plasma creatinine (PCr) level, TI lesions, DNA-repair
processes (proliferating cell nuclear antigen tissue expression),
and AA-DNA adduct formation were quantified in each group
after 2, 4, 5, and 8 days of AA injections.
PBN prevents AA-induced acute kidney injury
A transient acute kidney injury, as reflected by a significant
increase in PCr levels, was observed in mice receiving AA after
5 days of injections as compared with control animals (PCr
(mg/dl), median (min–max): 0.353 (0.222–0.504) vs 0.135
(0.112–0.211); Po0.0022). The addition of PBN prevents PCr
increase in AA animals (PCr (mg/dl), median (min–max):
0.125 (0.105–0.139) vs 0.353 (0.222–0.504); Po0.0022). No
significant change in PCr levels was measured in the
PEGþ PBN group as compared with controls (Figure 2).
PBN significantly reduces AA-induced TI injury
As demonstrated in Figures 3 and 4a–h, the renal parenchyma
from PEG and PEGþ PBN groups remained normal in
optical microscopy analyses at all studied time points of the
protocol. In contrast, early histological lesions were present
in the AA group (Figures 3 and 4i–l). As early as day 2, a
swelling of PTECs was found in the medullary rays (Figure
4i). In the same areas, prominent PTEC necrosis was
observed at days 4 and 5 (Figures 3 and 4j–k). After 8 days
of AA treatment, tubular atrophy was clearly widespread as
reflected by dilatation and flattening of PTECs, as well as
tubular basement membrane thickening. In the surrounding
interstitial areas, mononuclear cell infiltration was observed
at day 4 and progressively extended to day 8. At that time
point, this inflammatory process was associated with
extracellular matrix deposition. In mice receiving AAþ PBN,
swelling and necrosis of PTECs was limited to few tubules
located in the medullary rays only at day 4 without any
interstitial inflammatory cell infiltration (Figures 3 and 4n).
Moreover, proximal tubules, as well as the surrounding
interstitial areas, appeared normal under optical microscopy
analysis at days 5 and 8 (Figures 3 and 4o–p). Throughout the
protocol, no abnormality was detected within the glomeruli
from all groups under optical microscopy analysis.
As compared with controls, the semiquantitative score of
TI injury obtained in AA-treated mice revealed tubular
necrosis from day 4 to 8, with an evident peak at day 5
(Figure 5a), lymphocytic infiltration from day 5 (Figure 5b),
and marked tubular atrophy at day 5 accompanied by
progressive interstitial fibrosis (Figure 5c and d, respectively).
In the AAþ PBN group, a significant reduction of all the
semiquantitative scores was found: of tubular necrosis on
days 5 (Po0.0013) and 8 (Po0.0025), of lymphocytic
infiltrate (Po0.0013), of tubular atrophy (Po0.0018) (day 8),
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Figure 1 | Schematic representation of experimental protocols
performed in the mouse model of aristolochic acid
nephropathy (AAN). C57BL/6 male mice (n¼ 96) were
randomized in four groups of 24 mice each. Aristolochic acid (AA)
(5mg/kg body weight) was injected once a day and probenecid
(PBN) (150mg/kg body weight) twice a day. After 2, 4, 5, and 8
days of injection, six mice/group were killed and blood sample
and kidneys were harvested for further analysis.
0.5
0.4
0.3
0.2
0.1
0.0P
la
sm
a 
cr
ea
tin
in
e 
(m
g/d
l)
2 4
Time (days)
**
**
5 8
Figure 2 | Evolution of plasma creatinine levels. Plasma
creatinine from aristolochic acid (AA) (white columns),
AAþprobenecid (PBN) (gray columns)-treated mice as compared
with polyethylene glycol (PEG)þ PBN (dashed columns), and PEG
(dotted columns) controls from days 2 to 8. Results are presented
as the mean±s.e.m.; n¼ 6 mice per group (**Po0.01).
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as well as of interstitial fibrosis, on days 5 (Po0.0022) and 8
(Po0.0013) (Figure 5a–d).
Necrosis of positive neutral endopeptidase (NEP) tubules is
prevented by PBN
To further assess the distribution of necrotic tubules, an
immunostaining of NEP was performed and evaluated. NEP
is a specific marker for the brush border of S3 segment of the
proximal tubule in rats.21 As shown in Figure 6, immuno-
staining of NEP in control groups demonstrated that NEP-
positive cells were mainly located in medullary rays and in
the outer stripe of the outer medulla, reproducing the
typical distribution of NEP-positive cells in pars recta of
proximal tubule observed previously in our rat model.11,22
No disappearance of NEP immunostaining was observed in
the PEG or PEGþ PBN groups. AA administration led to a
progressive necrosis of PTECs, especially NEP positive, as
suggested by the progressive disappearance of NEP staining
in the medullary rays and the presence of intratubular
necrotic NEP-positive cells on day 5 (Figure 6c). At day 8,
NEP-positive cells had completely disappeared from
medullary rays (Figure 6d). On the contrary, NEP
immunostaining was maintained in the AAþ PBN group
(Figure 6e and f).
Addition of PBN leads only to a mild reduction of AA-DNA
adduct formation
As PBN administration was effective in significantly prevent-
ing acute kidney injury and TI lesions induced by AA, we
examined the possible effect of PBN on AA-DNA adduct
formation in kidney cortex tissue samples. As shown in Figure
7a, the pattern of AA-DNA adducts consisted of three major
adduct spots: 7-(deoxyadenosin-N6-yl)-aristolactam I (dA-
AAI, spot 1), 7-(deoxyguanosin-N2-yl)-aristolactam I (dG-
AAI, spot 2), and 7-(deoxyadenosin-N6-yl) aristolactam II
(dA-AAII, spot 3). This pattern is identical to those observed
previously in our rat model and in AA-exposed patients.6,22
In the AAþ PBN group, as compared with the AA group,
there were no significant changes in AA-DNA adducts at days
2, 4, and 5, whereas a significant reduction of the total AA-
DNA adduct levels was observed at day 8 (Figure 7b). There
was no correlation between the PCr levels or the TI scores
and AA-DNA adduct formation (data not shown).
Previous in vivo studies showed that DNA adduct formation
by AA reaches a steady-state level, which is likely the result of
a balance between adduct formation and their loss through
either DNA-repair processes or apoptosis.22,23 Moreover, this
level seems to be reached quickly, even 2 days after the first
injection in a rat model.22 This could explain the only small
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Figure 3 |Histological analysis of tubulointerstitial injury in aristolochic acid (AA)-treated mice compared with mice receiving
AAþprobenecid (PBN). Representative photomicrographs of renal cortex longitudinal sections at studied time points in each group. No
lesions were observed in controls: (a–d) polyethylene glycol (PEG) and (e–h) PEGþ PBN. (i–l) In the AA group, tubular necrosis (arrow) was
observed at days 4 and 5 in the outer stripe of the outer medulla. (m–p) In the AAþ PBN group, only sparse proximal tubules exhibited
necrotic cells on day 4 (arrow), but lymphocytic infiltrate, tubular atrophy, and interstitial fibrosis were absent on day 8. Original
magnification  400, hematoxylin–eosin-stained kidney longitudinal sections.
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differences in DNA adduct levels between the two groups after
8 days of treatment. Therefore, we conducted an additional
experiment to investigate the early time course and kinetics
of AA-DNA adduct formation. Thirty-two mice were injected
with AA or AAþ PBN as described previously, and four mice
per group were killed after 6, 12, 18, and 24 h. At these time
points, differences in AA-specific DNA adduct levels between
the two groups were clearly observed (Figure 7a), confirming
that PBN significantly inhibits AA-DNA adduct formation.
PBN significantly reduces AA-induced DNA-damage-repair
processes and cell proliferation attested by PCNA
immunostaining
PCNA is a polymerase cofactor, involved in DNA-damage-
repair processes and in the stability of the DNA microsatellite
region.24 Only few tubular cells expressed PCNA in controls
(PEG and PEGþ PBN groups) (Figure 8a–h). In AA-treated
mice, typical nuclear patterns of PCNA immunostaining were
predominantly seen in PTECs and less frequently in
interstitial cells from the corticomedullary junction as soon
as day 2 and still increased until day 8 (Figure 8i–l). PBN
administration resulted in a reduction of PCNA expression
induced by AA in mice as soon as day 4 (Figure 8m–p).
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Figure 4 |Histological analysis of tubulointerstitial injury in aristolochic acid (AA)-treated mice compared with mice receiving
AAþprobenecid (PBN). Representative photomicrographs of renal cortex longitudinal sections at studied time points in each group. No
lesions were observed in controls: (a–d) polyethylene glycol (PEG) and (e–h) PEGþ PBN. (i–l) In the AA group, swelling of proximal tubular
epithelial cells was observed after 2 days of injection ($), followed by tubular necrosis at days 4 and 5 (arrow). Tubular atrophy (star) and
progressive interstitial fibrosis (arrowhead) were present after 8 days of injection. (m–p) In the AAþ PBN group, tubular atrophy and
interstitial fibrosis were absent on day 8. Original magnification  400, Goldner’s trichrome–stained kidney longitudinal sections.
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Figure 5 | Semiquantitative tubulointerstitial score. In control
groups (polyethylene glycol (PEG) or PEGþprobenecid (PBN)), no
lesions were observed (data not shown). However, a significant
increase in the necrosis score was observed in the aristolochic
acid (AA) group (white columns) as soon as day 4 and (a) was
maximal on day 5 as compared with controls. Tubular necrosis
phase was followed by the presence of (b) a significant
lymphocytic infiltrate, (c) atrophy, and (d) fibrosis, respectively, on
day 8. A significant reduction of necrosis, atrophy, and fibrosis was
observed in the AAþ PBN group (gray columns). Results are
presented as the mean±s.e.m., n¼ 6 mice per group. Significant
levels are **Po0.01.
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As compared with controls, the proportion of PCNA
positively stained areas per field was higher in AA-treated
mice from day 5 (Po0.0043) to day 8 (Po0.0152) (Figure
8q). This proportion was significantly decreased in the
AAþ PBN group at day 5 (Po0.0043) and day 8 (Po0.0022)
(Figure 8q).
PBN reduces the degree of ultrastructural lesions of PTECs
induced by AA
Control groups (PEG and PEGþ PBN) exhibited only mild
mitochondrial swelling in few PTECs at day 8 (Figure 9a and
b). In kidneys from AA-treated mice, considerable variation in
the degree of cellular damage may occur. Normal tubules were
frequently admixed with injured nephron showing extensive
mitochondria disruption and altered brush borders (Figure 9c
and e). PBN administration reduced both the extent and the
severity of cellular damage induced by AA (Figure 9d and f).
DISCUSSION
Since the cluster outbreak of the so-called Chinese herbs
nephropathy in 1993, AAN is now recognized as a public
health problem worldwide:25 it is identified as an environ-
mental kidney disease in the Balkan region and probably
underestimated in Asian countries where traditional Chinese
medicine is widely used, as suggested by two recent
studies.26,27 Understanding its physiopathology may lead to
effective therapies, preventing the progression of chronic
kidney disease.
In the present study, we reproduced histopathological
features of human AAN (tubular necrosis, inflammatory
interstitial infiltrate, tubular atrophy, and interstitial fibrosis)
in a short-term mouse model. Male C57BL/6 mice were
injected daily with a mixture of AAI and AAII, the same as
the one present in Aristolochia sp. and ingested by our
patients. After 4 days of injection, a massive necrosis of
PTECs from the medullary rays was observed, resulting in an
acute kidney injury on day 5. This ‘acute’ phase was followed
by a prominent atrophy and fibrosis on day 8. The
normalization of creatinine on day 8 is consistent with our
observations of the acute phase in the AAN rat model, in
which a transient creatinine increase on day 5 was followed
by a normalization of creatinine on day 8, contrasting with
persistent histological lesions.22 In addition, such dissocia-
tion between PCr and histology during the recovery phase
has been described in other models of acute kidney injury
such as ischemia and reperfusion.28
The addition of PBN prevented acute kidney injury and
significantly reduced tubular necrosis, lymphocytic infiltrate,
atrophy, and fibrosis. Moreover, immunohistochemical study
using PCNA staining confirmed the protective effect of PBN
from AA. Increase in PCNA staining reflects a proliferation
process of PTECs secondary to necrosis, which is in accordance
with previous histological findings obtained in our rat model
using Ki67 immunostaining.12 Finally, a reduction of AA-DNA
adduct formation was found in mice receiving AAþ PBN as
compared with mice treated with AA alone.
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Figure 6 |Representative photomicrographs of neutral
endopeptidase (NEP) staining in different groups and time. In
control groups ((a, b) polyethylene glycol (PEG)), a NEP-positive
staining was observed in medullary rays and in the outer stripe of
the outer medulla. An identical distribution was observed in the
PEGþ probenecid (PBN) group (data not shown). (c, d) However,
in the aristolochic acid (AA) group, a severe necrosis followed by a
profound atrophy of proximal tubular epithelial cells was
observed mainly in the NEP-positive area corresponding to the S3
segment of the proximal tubule. (e, f) In the AAþ PBN group,
necrosis was limited (original magnification:  200).
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Figure 7 |Time course of aristolochic acid (AA)-DNA adduct
formation in renal tissue. Total AA-DNA adduct formation was
determined by 32P-postlabeling in the AA (white columns) and
AAþ probenecid (PBN) groups (gray columns) in two separate
experiments from 6 to 24 h and from day 2 to day 8. As shown in
(a), the pattern of AA-DNA adducts consisted of three major
adduct spots: 7-(deoxyadenosin-N6-yl)-aristolactam I (dA-AAI; spot
1); 7-(deoxyguanosin-N2-yl)-aristolactam I (dG-AAI; spot 2); and
7-(deoxyadenosin-N6-yl)-aristolactam II (dA-AAII; spot 3). (b) Results
are presented as the mean±s.e.m. n¼ 4 mice per group (6–24 h)
or n¼ 6 (2–8 days) per group. Significant levels are *Po0.05 and
**Po0.01.
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Recently, two in vitro studies demonstrated that PBN
inhibits AA entry in human OAT-transfected HEK293 kidney
cell lines19 and human OAT-transfected cell lines derived
from the second portion of the proximal tubule.18 Further,
the former study indicated that PBN can reduce AA-DNA
adduct formation and that addition of PBN to AA preserved
cellular viability. The present work brings significant in vivo
results confirming the protective effects of PBN against AA-
induced TI lesions by blocking AA entry into PTECs via
OATs. Actually, these histomorphometric data can be related
to a recent pharmacological study, focusing on the effects of
PBN on AA liver and kidney metabolism.29 These authors
reported a significantly reduced accumulation of renal AAI in
mice exposed to AA and PBN, as well as an increase in AAI
liver content and biliary clearance.
With regard to the evident protective effect of PBN in
terms of TI AA-induced lesions, it could be surprising to
measure a only slight difference of AA-DNA adduct level
between the AA and AAþ PBN groups. However, this discrep-
ancy could be easily interpreted. First of all, in the AAþ PBN
group, AA may enter PTECs independently of OAT. Other
endogenous transmembrane transporters or passive diffusion
may also be involved in the uptake of AA, as suggested by a
only partial blockade of AA entry by PBN in an in vitro model of
human OAT-transfected HEK293 cells.19 Second, DNA adduct
formation by AA often quickly reaches a steady-state level as
seen in previous in vivo studies and our present results. In
addition, our data suggest that although AA-DNA adducts
are a clue biomarker of AA exposure, there is no correlation
between AA-specific DNA adduct levels and nephrotoxicity.
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Figure 8 |Representative photomicrographs of proliferating cell nuclear antigen (PCNA) staining in different groups and time
points with quantification. In control groups ((a–d) polyethylene glycol (PEG) and (e–h) PEGþprobenecid (PBN)), only scattered PCNA-
positive PTECs were observed as compared (i–l) with the aristolochic acid (AA) group where numerous PCNA-positive PTECs were present.
(m–p) Coadministration of PBN and AA resulted in a substantial reduction of PCNA-positive PTECs on day 8 (original magnification:  400).
(q) Quantification of positive PCNA cells in AA (white columns), AAþ PBN (gray columns), PEGþ PBN (dashed columns), and PEG groups
(dotted columns). Results are presented as the mean±s.e.m.; n¼ 6 mice per group. Significant levels are *Po0.05, **Po0.01.
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Dissociation between AA-mediated nephrotoxicity and
adduct formation was first suggested by a clinical case report
of AA-induced tumor development without renal impair-
ment.30 This observation was followed by two rodent studies
showing that AA-DNA adducts were the basis for the
carcinogenic effect of AA but were unrelated to nephrotoxic
insult. Indeed, both AAI and AAII could cause similar types
of DNA damage (i.e., bulky DNA adducts), whereas only AAI
is nephrotoxic in vivo.9,10 In vitro studies confirmed that AAI
is much more cytotoxic compared with AAII because of the
presence of a methoxy group in position 8.31,32 On the other
hand, the carboxyl group rather than the nitro group is
important to facilitate AA entry into tubular cells via OATs.
Finally, nitroreduction results in N-hydroxy-aristolactam
formation, and these metabolites bind covalently to the
exocyclic amino groups of adenine or guanine forming AA-
specific DNA adducts.33,34 On the other hand, AAI seems to
directly cause renal injury by activating mitochondrial
permeability transition,35 and reticulum endoplasmic
stress.36 Further, AA is responsible for increased oxidative
stress–related DNA lesions due to glutathione depletions,37
and AA can block DNA replication causing cycle arrest and/
or apoptosis in renal epithelial cells in vitro and in vivo.38–40
In conclusion, we developed an in vivo model of AAN
characterized by an early episode of acute kidney injury
induced by daily injections of AA. Despite highly nephrotoxic
effects of AA, we were able to demonstrate a sustained
protective effect of PBN by blocking AA entry into PTECs
and then preventing acute tubular necrosis.
MATERIALS AND METHODS
Experimental protocols
All procedures were in accordance with the Ethical Committee for
Animal Care (Faculty of Medicine, Universite´ Libre de Bruxelles).
After 1 week of acclimatization, 10-week-old C57BL/6 male mice,
n¼ 96 (Elevage Janvier, Le Genest Saint-Isle, France), were
randomly assigned to four groups of 24 mice each and were
injected intraperitoneally with solvent (PEG group) alone,
PEGþPBN (4-((dipropylamino)sulfonyl)benzoic acid) (PEG
group), AA (AA group), or AAþPBN (AAþ PBN group). AA
(Acros Organics, Geel, Belgium; 40% AAI and 60% AAII) was
dissolved in PEG (Fluka Chemie, Buchs, Switzerland). PBN (Sigma-
Aldrich, Bornem, Belgium) was solubilized in 0.5mol/l NaOH at
45 1C for 10min and then diluted with phosphate-buffered saline
and buffered to pH 7.4 with HCl. AA (5mg/kg body weight) or an
equivalent volume of PEG was given once a day and PBN (150mg/
kg body weight) twice a day. AA was given once a day
intraperitoneally in 150 ml of solvent, and PBN (150mg/kg body
weight) was injected with 150 ml of phosphate-buffered saline twice a
day for a total of 8 days maximum. After 2, 4, 5, or 8 days of injection,
six mice per group were killed. After intraperitoneal anesthesia with
ketamine-HCl (Merial, Brussels, Belgium) and 2% xylazine (Bayer,
Brussels, Belgium), a blood specimen was obtained by cardiac
puncture and kidneys were harvested for analysis. Different samples
of kidneys were fixed: one part in alcohol–formalin–acetic acid for
optical microscopy, one in 4% buffered formaldehyde for im-
munohistochemistry, one in glutaraldehyde sodium cacodylate buffer
for electron microscopy analysis, and one frozen in liquid nitrogen
and stored at 80 1C for subsequent DNA adduct analysis.
Renal histopathology
TI injury semiquantification was evaluated on hematoxylin/eosin
and Masson’s trichrome–stained paraffin-embedded sections. Com-
plete kidney sections were analyzed with a light microscope (Carl
Zeiss, Oberkochen, Germany) using a  20 magnification lens by
two investigators (AAP and TB) blinded to the group origin of the
mice. The scoring systems were defined as previously described:11,12
tubular necrosis: 0, normal tubules; 1, rare single necrotic tubule; 2,
several clusters of necrotic tubules; 3, confluence of necrotic clusters;
tubular atrophy: 0, normal tubules; 1, rare single atrophic tubule; 2,
several clusters of atrophic tubules; 3, confluence of atrophic tubular
clusters; lymphocytic infiltrate: 0, absent; 1, few scattered cells; 2,
group of lymphocytes; 3, widespread infiltrate; interstitial fibrosis: 0,
absent; 1, minimal fibrosis; 2, moderate fibrosis; 3, severe fibrosis. If
differences in grading occurred, the appropriate sections were
reexamined until a consensus was obtained.
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Figure 9 |Representative electron photomicrographs from
different groups on day 8. Kidneys from (a) polyethylene glycol
(PEG) (original magnification  3000) and (b) PEGþprobenecid
(PBN) (original magnification  5000) groups: proximal tubules (d)
are lined by tall columnar cells with acidophilic cytoplasm rich in
structures necessary for active fluid transport—densely packed
microvilli forming brush border, basal undulations, endocytic
vacuoles, and mitochondria, often elongated and tortuous. (c) In
the aristolochic acid (AA) group (original magnification  3000),
proximal tubular epithelial cells (PTECs) exhibited severe injury
with the disruption of brush border and cell detachment ($). (d) In
kidneys from the AAþ PBN group (original magnification  3000),
PTECs displayed extensive cytoplasmic vacuolization without
necrotic changes (**). (e) Kidneys from the AA group: (original
magnification  30,000) normal (d) and injured tubules were
frequently admixed with injured nephron showing extensive
mitochondria disruption (arrow head) and altered brush borders.
(f) The AAþ PBN group (original magnification  30,000)
displayed mitochondria vacuolization (arrow head).
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Biochemical evaluation of renal function
PCr excretion levels were determined as previously described using
an high-performance liquid chromatography technique.11,12
Immunohistochemistry
The formalin fixed paraffin embedded sections (4 mm) were attached
to poly-L-lysine-pretreated slides (Sigma-Aldrich). After air-drying
the paraffin from FFPE, tissue sections were removed (xylene
solution). The sections were rehydrated and immersed in a retrieval
solution, sodium citrate buffer (pH 6.0); the microwave oven
technique was used (650W, 1 5min). Phosphate-buffered saline
was used for all washing steps. Endogenous peroxidase activity was
quenched with 0.3% hydrogen peroxide in a methanol solution
(30min). Nonspecific protein-binding sites (background staining
due to the Fc receptor) were blocked with 20% normal serum
(Vectastain Elite ABC kit IgG; Vector Laboratories, Labconsult,
Brussels, Belgium) and then with avidin D and biotin solution
(avidin/biotin blocking kit; Vector Laboratories, Labconsult).
Subsequently, the sections were incubated overnight with rabbit
anti-mouse PCNA (1/4000) monoclonal primary antibody (Abcam,
Cambridge, England, UK, ab2426) or with rat monoclonal antibody
anti-NEP (1/4000) (Santa Cruz Biotechnology, Boechout, Belgium,
sc-80021) and diluted in the blocking buffer. Slides were then
incubated with specific biotinylated secondary antibody (Vectastain
Elite ABC kit; Vector Laboratories, Labconsult). The extent of the
specifically bound primary antibodies was visualized by means of
the avidin–biotin peroxidase complex method. The diaminobenzi-
dine/hydrogen peroxide was used as the chromogene substrate,
producing a brown end product. Counterstaining with hematoxylin
completed the processing. The specificity of antibodies used was
established by the producer. Normal serum (5% solution) instead of
the primary antibody (used in order to exclude nonspecific staining
of kit reagents) showed no staining.
Quantification of PCNA immunostainings
Quantifications were performed by one investigator (TB) blinded to
the group origin of the mice using ImageJ, a public domain Java
image processing program (US NIH) software (available at http://
rsb.info.nih.gov/ij), as detailed in Figure 10. Thresholding condi-
tions were set identically for all images. Finally, the percentage of
3,30-diaminobenzidine-positive surface corresponding to 3,30-dia-
minobenzidine-positive cells was counted using the ImageJ analyse
particle command.
Ultrastructural analysis
Analysis of cellular ultrastructure using transmission electron
microscopy was performed in the same period. Small pieces of renal
tissue were fixed in 3% glutaraldehyde in 0.1mol/l phosphate buffer,
pH 7.2. Fixation was performed with the microwave oven technique.
After rinsing, samples were postfixed in 1% osmium tetroxide in
0.1mol/l phosphate buffer for 1 h at 4 1C, processed through a graded
acetone series, embedded in Araldite (TAAB Laboratories, Aldermaston,
England, UK), and polymerized overnight at 60 1C. Sections (50nm)
were then stained with uranyl acetate and lead citrate and examined
with a 10-10 JEOL electron microscope (JEOL, Tokyo, Japan).
AA-DNA adduct analysis
DNA was extracted from frozen tissues using a standard phenol–-
chloroform extraction method. 32P-postlabeling analysis,41 nuclease
P1 enrichment, chromatography on polyethyleneimine-cellulose thin-
layer plates (Macherey and Nagel, Du¨ren, Germany), autoradiography
using a Packard Instant Imager (Canberra, Downers Grove, IL), and
quantification were essentially performed as described.42 Results were
expressed as DNA adducts per 108 normal nucleotides.
Statistical analysis
All the scores and data obtained from AA and control groups were
compared for each corresponding time point with the Kruskall–-
Wallis test followed by Mann–Whitney U-test and Bonferroni post-
hoc test.
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